GlassScriptPhysician profile
Lihong Huo
NPI 1003173287
$1,370.67
in general payments reported to CMS, 2019-2025
19 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.04 · 2021: $167 · 2022: $243 · 2023: $392 · 2024: $155 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887 · Education: $16.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.19 |
| Education | $16.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $299.86 | 2021-2025 | Ozempic |
| Abbott Laboratories | $133.30 | 2022-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $129.60 | 2023-2025 | Minimed 780g, Intellis Adaptivestim, Minimed 630g |
| Corcept Therapeutics | $121.73 | 2022-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $99.88 | 2019-2023 | |
| Ascendis Pharma Endocrinology INC | $88.11 | 2023-2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $84.63 | 2022 | |
| Lilly USA, LLC | $72.08 | 2022-2024 | Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $61.68 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $42.86 | 2023 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $41.37 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.85 | 2024 | Jardiance |
| Sequel Med Tech, LLC | $30.82 | 2025 | Twiist |
| Amgen INC. | $28.88 | 2025 | |
| Radius Health, INC. | $27.76 | 2023 | Tymlos |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $20.27 | 2023 | Isturisa, Signifor Lar |
| Astellas Pharma US INC | $19.85 | 2025 | Veozah |
| Dexcom, INC. | $19.31 | 2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $15.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lihong Huo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.